GlassScriptPhysician profile
Kerri Kittrell
NPI 1992975056
$1,275.45
in general payments reported to CMS, 2019-2025
24 companies · $278 in 2025
The $278 reported for 2025 was more than what a typical Primary Care provider received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $319 · 2022: $228 · 2023: $361 · 2024: $89.41 · 2025: $278.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $728.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $728.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $263.01 | 2023-2025 | Breztri, Farxiga, Bevespi Aerosphere |
| Bayer Healthcare Pharmaceuticals INC. | $161.42 | 2022-2025 | |
| Abbvie INC. | $122.53 | 2021-2024 | |
| Lilly USA, LLC | $80.90 | 2021-2022 | |
| Astellas Pharma US INC | $76.17 | 2021 | |
| Exact Sciences Corporation | $64.09 | 2023 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $54.36 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.44 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $44.75 | 2024 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $37.25 | 2025 | |
| Janssen Pharmaceuticals, INC | $34.51 | 2021-2023 | Spravato |
| Glaxosmithkline, LLC. | $32.33 | 2021-2022 | |
| Amgen INC. | $31.16 | 2023-2024 | Prolia, Evenity |
| Biohaven Pharmaceuticals, INC. | $29.62 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $28.56 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $26.40 | 2025 | Barrigel |
| Novo Nordisk INC | $19.70 | 2022 | |
| Ibsa Pharma INC. | $19.55 | 2023 | Tirosint, Licart |
| Pfizer INC. | $19.36 | 2022 | |
| Ironwood Pharmaceuticals, INC | $18.59 | 2021 | |
| Genentech USA, INC. | $18.27 | 2021 | |
| Sumitomo Pharma America, INC. | $16.51 | 2023 | Gemtesa |
| Amarin Pharma, INC. | $14.97 | 2021 | |
| Sanofi-Aventis U.S. LLC | $12.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kerri Kittrell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.